Cargando…
Assessment of Tau Pathology as Measured by (18)F-THK5317 and (18)F-Flortaucipir PET and Their Relation to Brain Atrophy and Cognition in Alzheimer’s Disease
BACKGROUND: In Alzheimer’s disease (AD), the abnormal aggregation of hyperphosphorylated tau leads to synaptic dysfunction and neurodegeneration. Recently developed tau PET imaging tracers are candidate biomarkers for diagnosis and staging of AD. OBJECTIVE: We aimed to investigate the discriminative...
Autores principales: | Colato, Elisa, Chiotis, Konstantinos, Ferreira, Daniel, Mazrina, Mariam S., Lemoine, Laetitia, Mohanty, Rosaleena, Westman, Eric, Nordberg, Agneta, Rodriguez-Vieitez, Elena |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
IOS Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8609906/ https://www.ncbi.nlm.nih.gov/pubmed/34511502 http://dx.doi.org/10.3233/JAD-210614 |
Ejemplares similares
-
[(18)F]THK5317 imaging as a tool for predicting prospective cognitive decline in Alzheimer’s disease
por: Chiotis, Konstantinos, et al.
Publicado: (2020) -
Optimal timing of tau pathology imaging and automatic extraction of a reference region using dynamic [(18)F]THK5317 PET
por: Jonasson, My, et al.
Publicado: (2019) -
Regional tau deposition measured by [(18)F]THK5317 positron emission tomography is associated to cognition via glucose metabolism in Alzheimer’s disease
por: Saint-Aubert, Laure, et al.
Publicado: (2016) -
Imaging in-vivo tau pathology in Alzheimer’s disease with THK5317 PET in a multimodal paradigm
por: Chiotis, Konstantinos, et al.
Publicado: (2016) -
In vivo imaging of tau deposition in Alzheimer’s disease using both [(18)F]-THK5317 and [(18)F]-S16: A pilot human study
por: Fu, Liping, et al.
Publicado: (2022)